Cosmo Pharmaceuticals Confirms No Exposure to Proposed U.S. Tariffs and Reaffirms Growth Momentum
Cosmo Pharmaceuticals (OTC:CMOPF) has addressed market concerns regarding potential U.S. tariffs on Swiss pharmaceutical companies, confirming that its operations and revenue streams remain unaffected. The company emphasized that it does not export products from Switzerland to the United States and operates through long-term contracts with global partners.
The company has reported increased EBITDA in its latest half-year results and maintains a positive outlook on its growth trajectory, supported by strong fundamentals and continued execution of its strategic plan.
Cosmo Pharmaceuticals (OTC:CMOPF) ha rassicurato il mercato riguardo a possibili dazi statunitensi sulle aziende farmaceutiche svizzere, confermando che le sue operazioni e i flussi di ricavi non sono influenzati. L'azienda ha sottolineato che non esporta prodotti dalla Svizzera agli Stati Uniti e opera tramite contratti a lungo termine con partner globali.
Nei risultati dell'ultimo semestre, la societ脿 ha registrato un aumento dell'EBITDA e mantiene una prospettiva positiva sulla sua crescita, supportata da solidi fondamentali e dalla continua attuazione del piano strategico.
Cosmo Pharmaceuticals (OTC:CMOPF) ha tranquilizado al mercado sobre posibles aranceles estadounidenses a las compa帽铆as farmac茅uticas suizas, confirmando que sus operaciones y fuentes de ingresos no se ven afectadas. La empresa destac贸 que no exporta productos desde Suiza a Estados Unidos y opera mediante contratos a largo plazo con socios globales.
En sus resultados del 煤ltimo semestre, la compa帽铆a report贸 un aumento en el EBITDA y mantiene una perspectiva positiva de crecimiento, respaldada por fundamentos s贸lidos y la continua ejecuci贸n de su plan estrat茅gico.
旖旍姢氇� 韺岆鞀堩嫲旎姢 (OTC:CMOPF)電� 氙戈淡鞚� 鞀れ渼鞀� 鞝滌暯靷棎 攵�瓿柬暊 靾� 鞛堧姅 甏�靹胳棎 雽�頃� 鞁滌灔 鞖半牑毳� 頃挫唽頃橂┌ 鞛愳偓鞚� 鞖挫榿瓿� 靾橃澋 頋愲鞚� 鞓來枼鞚� 氚涭 鞎婋姅雼り碃 頇曥澑頄堨姷雼堧嫟. 須岇偓電� 鞀れ渼鞀れ棎靹� 氙戈淡鞙茧 鞝滍拡鞚� 靾橃稖頃橃 鞎婌溂氅� 旮�搿滊矊 韺岉姼雱堨檧 鞛リ赴 瓿勳暯鞚� 韱淀暣 鞖挫榿頃橁碃 鞛堧嫟瓿� 臧曥“頄堨姷雼堧嫟.
斓滉芳 氚橁赴 鞁れ爜鞐愳劀 EBITDA臧� 歃濌皜頄堨溂氅�, 瓴碃頃� 旮半掣 觳措牓瓿� 鞝勲灥 瓿勴殟鞚� 歆�靻嶌爜鞚� 鞁ろ枆鞚� 氚旐儠鞙茧 靹膘灔 鞝勲鞚� 旮嶌爼鞝侅溂搿� 鞙犾頃橁碃 鞛堨姷雼堧嫟.
Cosmo Pharmaceuticals (OTC:CMOPF) a apais茅 les inqui茅tudes du march茅 concernant d'茅ventuels tarifs am茅ricains sur les entreprises pharmaceutiques suisses, confirmant que ses op茅rations et ses sources de revenus restent inchang茅es. La soci茅t茅 a soulign茅 qu'elle n'exporte pas de produits de Suisse vers les 脡tats-Unis et fonctionne via des contrats 脿 long terme avec des partenaires mondiaux.
Dans ses derniers r茅sultats semestriels, l'entreprise a enregistr茅 une augmentation de l'EBITDA et maintient une perspective positive quant 脿 sa trajectoire de croissance, soutenue par des fondamentaux solides et la poursuite de l'ex茅cution de son plan strat茅gique.
Cosmo Pharmaceuticals (OTC:CMOPF) hat Marktbedenken bez眉glich m枚glicher US-Z枚lle auf Schweizer Pharmaunternehmen ausger盲umt und best盲tigt, dass seine Gesch盲ftst盲tigkeiten und Einnahmequellen unbeeintr盲chtigt bleiben. Das Unternehmen betonte, dass es keine Produkte aus der Schweiz in die USA exportiert und durch langfristige Vertr盲ge mit globalen Partnern operiert.
Im j眉ngsten Halbjahresbericht meldete das Unternehmen einen Anstieg des EBITDA und beh盲lt einen positiven Ausblick auf seine Wachstumsentwicklung bei, gest眉tzt auf solide Fundamentaldaten und die fortgesetzte Umsetzung seines strategischen Plans.
- Company confirms no exposure to potential U.S. tariffs on Swiss pharmaceuticals
- Operations secured through long-term contracts with global partners
- Increased EBITDA reported in latest half-year results
- None.
Dublin, Ireland--(Newsfile Corp. - August 6, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) notes the recent market volatility following reports on potential U.S. tariffs on Swiss pharmaceutical companies.
Cosmo confirms that its operations and revenue streams are not impacted by any potential U.S. tariff measures, as the Company does not export products from Switzerland to the United States and operates on long-term contracts with global partners.
Cosmo remains confident in its growth trajectory, supported by the Company’s strong fundamentals and recently increased EBITDA, as reported in the latest half-year results. The Company continues to execute on its strategic plan, delivering stable and reliable performance for its shareholders.
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy).
For more information, visit .
Financial calendar
| | |
For further information, please contact:
[email protected]
Attachments
To view the source version of this press release, please visit
FAQ
Will Cosmo Pharmaceuticals (CMOPF) be affected by the proposed U.S. tariffs on Swiss pharmaceutical companies?
How does Cosmo Pharmaceuticals protect its revenue streams from trade uncertainties?
What was reported in Cosmo Pharmaceuticals' latest half-year results?
What is the current growth outlook for Cosmo Pharmaceuticals (CMOPF)?
